Nektar Therapeutics Announced Several Presentations For Rezpegaldesleukin At The 2024 European Academy Of Dermatology And Venereology Congress
Nektar Therapeutics Announces Multiple Presentations for Rezpegaldesleukin at EADV 2024
Iambic Therapeutics Announces the Addition of Dr. Mary Tagliaferri to Its Board of Directors
Nektar Management to Present at Upcoming Investor Conferences
Nektar Therapeutics Second Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
Nektar Therapeutics | 10-Q: Q2 2024 Earnings Report